Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Entera Bio Ltd. (ENTX)

Entera Bio Appoints Laura Hamill to Board as Yonatan Malca Steps Down

Neutral Impact 2 of 5 leadership Written later

Entera Bio Ltd. appointed biopharmaceutical executive Laura Hamill as a Class I director, effective December 1, 2026, and she will also join the audit and corporate governance and nomination committees. Director Yonatan Malca, who has served the company for 16 years, will step down from the board on the same date. The filing involves board composition only and does not include financial results or guidance.

Key points

  • Laura Hamill, age 62, joins the board effective December 1, 2026, and will serve on the audit and corporate governance and nomination committees.
  • Hamill was previously Executive Vice President, Worldwide Commercial Operations at Gilead Sciences and spent nearly two decades at Amgen.
  • Yonatan Malca steps down from the board effective December 1, 2026, and is not leaving over any disagreement with the company.
  • The Board has determined Hamill is independent under SEC and Nasdaq rules.

The filing

CompanyEntera Bio Ltd. (ENTX)
Form8-K, current report
Filed with the SECOct 6, 2026, 8:00 AM ET
Accession number0001178913-26-004720

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.